MarginsXMarginsX
Home › Markets › Health Care › ATRA

Atara Biotherapeutics Inc. (ATRA)

ATRA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$6.40
-16.88% on the day
Market cap
$65.2M
Micro cap
Revenue · 2025
$120.8M
-6.3% on 2024
Net income · 2025
$32.7M
27.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/0001193125-26-108361-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerATRA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2014
SEC CIK0001604464
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$120.8M
Net income$32.7M
Operating income$35.9M
Net margin27.1%
Operating margin29.7%
Revenue growth-6.3%
Cash$8.5M
Total assets$20.2M
P/E (computed)2.0×
P/S (computed)0.5×

Warning signs

Cash runway
3.7 months
$4.1M cash at September 30, 2026
Share count, 1 year
+41.3%
2025-11-06 to 2026-11-06 · +149.9% over 3 years
Going-concern doubt
Yes
10-Q filed November 10, 2026
Insider net buying, 12 months
$1.9M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Accordingly, we have concluded that substantial doubt exists with respect to our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements."
10-Q 2026-11-10
Cash and burn$4.1M cash; operating cash flow -$3.2M a quarter.Report 2026-09-30
Shares outstanding10,188,438 (2026-11-06); 7,210,235 a year earlier; 101,922,250 three years earlier. 3y figure adjusted for split (1-for-25 overall).Cover page 2026-11-06
Reverse splits, 3 years1; latest 1-for-25 on 2024-06-20Source 2024-06-20
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 2 424B5 takedowns, 1 at the marketLatest 2026-05-12
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-05-01
AuditorDeloitte & Touche LLP, San Francisco, California, United StatesPCAOB Form AP 2026-03-25
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $5.7M, sold $3.9M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.2M-$2.2M-$879K$4.1MNo debt tags$4.0M10-Q 2026-11-10
Q2 2026
2026-06-30
$630K-$4.8M-$3.3M$3.2MNo debt tags$6.2M10-Q 2026-08-12
Q1 2026
2026-03-31
$516K-$4.1M-$3.1M$8.4MNo debt tags$23.1M10-Q 2026-05-12
Q4 2025
2025-12-31
$1.6M-$3.4M-$5.7M$8.5MNo debt tags$120.8M10-K 2026-03-16
Q3 2025
2025-09-30
$3.5M-$4.3M-$9.8M$5.7MNo debt tags$151.9M10-Q 2025-11-12
Q2 2025
2025-06-30
$17.6M$2.4M-$7.3M$16.9MNo debt tags$188.7M10-Q 2026-08-12
Q1 2025
2025-03-31
$98.1M$38.0M-$28.1M$13.8MNo debt tags$199.7M10-Q 2026-05-12
Q4 2024
2024-12-31
$32.8M-$12.7M-$24.5M$25.0MNo debt tags$128.9M10-K 2026-03-16

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-11-10
Latest annual report10-K2026-03-16
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEF 14A2026-04-24

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.2%
1 month-17.2%
3 months-9.5%
Year to date-57.4%
1 year-42.5%
From 52-week high-57.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
CSBRChampions Oncology Inc.$4.68-0.53%$65.1M
CRDFCardiff Oncology Inc.$0.8477+16.75%$65.9M
OKYOOKYO Pharma Limited$1.18-12.96%$61.7M
NMRANeumora Therapeutics Inc.$0.3695-13.85%$69.4M
CGTXCognition Therapeutics Inc.$0.6388-6.03%$60.8M
PMCBPharmaCyte Biotech Inc.$5.57-16.62%$59.8M
AVXLAnavex Life Sciences Corp.$0.8176-12.42%$75.8M
TNYATenaya Therapeutics Inc.$0.3336-4.47%$76.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier